Evolution of systemic treatment for advanced hepatocellular carcinoma

Wu, Tsung-Che; Shen, Ying‐Chun; Cheng, Ann‐Lii

doi:10.1002/kjm2.12401

Cited by 14 publications

(11 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because there are currently no reliable and accurate prognostic biomarkers or models, the clinical prognosis of HCC patients continues to be a primary area of focus for research and development [ 23 , 24 ]. Over the course of the last ten years, a substantial amount of research has demonstrated that functional genes play an essential part in the progression of tumor growth [ 25 – 27 ]. It has been common knowledge among us that the clinical stage of HCC patients is connected to their overall prognosis.…”

Section: Discussionmentioning

confidence: 99%

Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma

Liu¹,

Zeng²,

Hong³

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) with high heterogeneity is one of the most frequent malignant tumors. However, there were no studies to create a clinical stage-related gene signature for HCC patients. Differentially expressed genes (DEGs) associated with clinical stage of HCC were analyzed based on TCGA datasets. Functional enrichment analysis was carried out by the use of stage-related DEGs. Then, the least absolute shrinkage and selection operator (LASSO) regression and univariate Cox regression were performed to reduce the overfit and the number of genes for further analysis. Next, survival and ROC assays were carried out to demonstrate the model using TCGA. Functional analysis and immune microenvironment analysis related to stage-related DEGs were performed. Reverse transcriptase polymerase chain reaction (RT-PCR) and Cell Counting Kit-8 (CCK-8) assays were applied to examine the expression and function of PNCK in HCC. In this research, there were 21 DEGs between HCC specimens with stage (I-II) and HCC specimens with stage (III-IV), including 20 increased genes and 1 decreased genes. A novel seven-gene signature (including PITX2, PNCK, GLIS1, SCNN1G, MMP1, ZNF488, and SHISA9) was created for the prediction of outcomes of HCC patients. The ROC curves confirmed the prognostic value of the new model. Cox assays demonstrated that the seven-gene signature can independently forecast overall survival. The immune analysis revealed that patients with low risk score exhibited more immune activities. Moreover, we confirmed that PNCK expressions were distinctly increased in HCC, and its silence suppressed the proliferation of HCC cells. Overall, our research offered a robust and reliable gene signature which displayed an important value in the prediction of overall survival of HCC patients and might deliver more effective personalized therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma

Liu¹,

Zeng²,

Hong³

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“… 19 As a tumor with rich blood supply, the recently developed antivascular molecular targeted therapy is a potential treatment strategy for patients who have lost the chance for radical surgery. 20 As the representative drug, sorafenib is associated with various side‐effects, including diarrhea, increased blood pressure, and skin lesions. 21 Moreover, cost implications and the extremely limited improvement in survival time greatly limits its clinical application prospects.…”

Section: Discussionmentioning

confidence: 99%

“…In the ranking of human malignant tumors, HCC has long occupied an important position with its high incidence and high mortality 19 . As a tumor with rich blood supply, the recently developed antivascular molecular targeted therapy is a potential treatment strategy for patients who have lost the chance for radical surgery 20 . As the representative drug, sorafenib is associated with various side‐effects, including diarrhea, increased blood pressure, and skin lesions 21 .…”

Section: Discussionmentioning

confidence: 99%

N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma, as one of the most common malignant tumors of the digestive system, ranks sixth in the number of new cases and is the second leading cause of cancer-related deaths globally, with a high incidence rate and a high degree of malignancy. 1 Tumors in HCC are frequently associated with an abundance of new blood vessels, which play a critical role in tumor growth, invasion, and metastasis. 2 As a result, the majority of patients lose the opportunity for radical surgery when diagnosed. 3 Therefore, targeting

show abstract

“…At the same time, targeted drugs also have adverse side effects, excessive use may shorten the survival period of patients. In addition, the low sensitivity of HCC cells makes chemotherapy have almost no impact on the overall survival rate of HCC patients ( 11 , 12 ). Therefore, it is urgent to determine an effective adjuvant method or drug that can effectively treat HCC and further inhibit the progress of HCC.…”

Section: Introductionmentioning

confidence: 99%

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Zou

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Because of its high prevalence and poor long-term clinical treatment effect, liver disease is regarded as a major public health problem around the world. Among them, viral hepatitis, fatty liver, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and autoimmune liver disease are common causes and inducements of liver injury, and play an important role in the occurrence and development of hepatocellular carcinoma (HCC). Tanshinone IIA (TsIIA) is a fat soluble polyphenol of Salvia miltiorrhiza that is extracted from Salvia miltiorrhiza. Because of its strong biological activity (anti-inflammatory, antioxidant), it is widely used in Asia to treat cardiovascular and liver diseases. In addition, TsIIA has shown significant anti-HCC activity in previous studies. It not only has significant anti proliferation and pro apoptotic properties. It can also play an anti-cancer role by mediating a variety of signal pathways, including phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and nuclear factor kappa-B (NF-κB). This review not only reviews the existing evidence and molecular mechanism of TsIIA’s anti-HCC effect but also reviews the liver-protective effect of TsIIA and its impact on liver fibrosis, NAFLD, and other risk factors for liver cancer. In addition, we also conducted network pharmacological analysis on TsIIA and HCC to further screen and explore the possible targets of TsIIA against hepatocellular carcinoma. It is expected to provide a theoretical basis for the development of anti-HCC-related drugs based on TsIIA.

show abstract

Evolution of systemic treatment for advanced hepatocellular carcinoma

Cited by 14 publications

References 77 publications

Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma

Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma

N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Contact Info

Product

Resources

About